Introduction: Why Liver Health Matters
The liver is our body’s multitool: it processes nutrients, detoxifies harmful substances, makes proteins and bile, and helps fend off infections. Yet it is vulnerable. Chronic viral infections, excessive alcohol use, fat buildup from obesity and insulin resistance, drug toxicity, and autoimmune attacks all inflame and injure liver tissue. Over time, this damage can disrupt metabolism and detoxification, leading to fibrosis, cirrhosis, and even liver failure or cancer. Worldwide, millions of lives are lost every year to liver disease, underscoring an urgent need for better treatments.
Key Messages
-
MSC Versatility: Mesenchymal stem cells (MSCs) reduce inflammation, curb fibrosis, and can become hepatocyte-like cells.
-
Exosome Advantage: Tiny vesicles secreted by MSCs carry proteins and RNAs that promote repair without the risks of whole-cell therapies.
-
Novel Mechanisms: MSC-derived exosomes protect against ferroptosis, modulate immune responses, and can be engineered to boost efficacy.
-
Clinical Promise: Early trials show improved liver function and survival in both acute and chronic liver failure models.
How MSCs Help the Injured Liver
MSCs are adult stem cells found in bone marrow, fat, umbilical cord and other tissues. They support liver repair in four main ways:
-
Homing and Engraftment
MSCs follow chemical signals to inflamed liver tissue and, in small numbers, differentiate into hepatocyte-like cells, helping to restore key functions. -
Immunomodulation
By secreting anti-inflammatory factors such as interleukin-10, MSCs shift immune cells toward healing phenotypes, reducing tissue-damaging inflammation. -
Anti-fibrotic Action
Through modulation of signaling pathways (TGF-β/Smad, STAT3, HGF), MSCs curb activation of collagen-producing cells, slowing or reversing scar formation. -
Paracrine Signaling via Exosomes
Much of MSC benefit comes from their released exosomes—nano-scale vesicles loaded with proteins, lipids and RNAs that reprogram injured cells and spur regeneration.
Exosomes: Cell-Free Repair Modules
Exosomes measure just 30–150 nm but pack a therapeutic punch. Compared with whole-cell therapies, MSC-derived exosomes:
-
Avoid Tumor Risks: They cannot proliferate uncontrollably.
-
Are Less Immunogenic: They carry fewer cell-surface antigens.
-
Offer Storage Stability: They can be preserved without loss of function.
Key therapeutic features include:
-
Ferroptosis Protection
Exosomes stabilize transporters that prevent iron-driven cell death in acute injury models. -
Immune Regulation
They deliver microRNAs and anti-inflammatory proteins that inhibit key inflammasome pathways, dampening harmful immune storms. -
Anti-fibrosis Synergy
Exosome cargo can enhance collagen breakdown and curb fibrotic signaling via pathways like Wnt/β-catenin and PTEN/AKT. -
Targeted Delivery
Surface modifications—such as adding specific ligands—improve uptake by injured hepatocytes, sharpening therapeutic focus.
Disease-Specific Applications
Acute Liver Failure & Ischemia-Reperfusion Injury
Studies show that exosomes reduce levels of IL-6, IL-1β and TNF-α, and limit neutrophil recruitment—key steps in reperfusion damage. A cell-free strategy could offer rapid, life-saving intervention.
Chronic Fibrosis & Cirrhosis
-
Exosomes from bone marrow and adipose MSCs inhibit collagen-producing cells, reducing scar tissue.
-
Engineered exosomes loaded with antifibrotic microRNAs more effectively restore extracellular matrix balance.
These findings suggest exosome therapy may slow or even reverse fibrotic progression, lowering the risk of cirrhosis-related complications.
Hepatocellular Carcinoma
-
Exosomes can carry pro-apoptotic and anti-angiogenic signals to tumor cells.
-
When enriched with specific microRNAs, they enhance cancer cell sensitivity to chemotherapy by targeting growth-promoting pathways.
This cell-free approach holds promise as a precision delivery vehicle for RNA-based cancer therapies.
From Bench to Bedside: Clinical Insights
-
Early Trials: Infusions of MSCs in acute-on-chronic liver failure have shown improvements in liver function scores and survival at six months. Treatment of decompensated cirrhosis has been safe and improved patient well-being.
-
Next Steps: Larger Phase III trials are needed to define optimal dosing, delivery routes, and long-term benefits.
Practical Implications and Future Directions
-
Standardization: Consistent manufacturing under good-practice conditions will ensure reliability across batches.
-
Mechanistic Clarity: Identifying which exosome cargoes drive specific repair pathways will refine therapies.
-
Combination Strategies: Pairing exosomes with small molecules or preconditioning agents may unlock synergistic effects.
-
Safety Monitoring: Though exosomes lack tumorigenic risk, off-target effects and immune reactions demand close surveillance.
Conclusion
MSCs and their exosomes represent a promising frontier in liver disease therapy. Combining targeted homing, immunomodulation, antifibrotic signaling and precision cargo delivery, these approaches could overcome many limitations of current drugs and transplants. As research advances toward standardized, large-scale trials, MSC-derived exosomes may soon become a cornerstone of regenerative hepatology.
引言：为何肝脏健康至关重要
肝脏是人体的“多功能工具”：它负责处理营养物质、解毒有害物质、合成蛋白质和胆汁，并帮助抵御感染。然而，肝脏也极易受损。慢性病毒感染、过量饮酒、肥胖和胰岛素抵抗导致的脂肪堆积、药物毒性以及自身免疫攻击，都会引发肝组织的炎症和损伤。随着时间推移，这些损伤会破坏代谢和解毒功能，进而导致肝纤维化、肝硬化，甚至肝衰竭或癌症。全球每年有数百万人死于肝脏疾病，凸显出迫切需要更好治疗手段的紧迫性。
关键信息
-
MSC 多功能性：间充质干细胞（MSCs）能够减轻炎症、抑制纤维化，并可分化为类肝细胞。
-
外泌体优势：MSCs 分泌的微小囊泡（外泌体）携带促进修复的蛋白和 RNA，可避免全细胞疗法的风险。
-
新颖机制：MSC 衍生外泌体可防止铁死亡、调节免疫反应，且可通过工程化手段增强疗效。
-
临床前景：早期试验显示，在急性和慢性肝衰竭模型中，肝功能和存活率均有所改善。
间充质干细胞如何帮助受损肝脏
MSCs 是存在于骨髓、脂肪、脐带等组织的成体干细胞，主要通过以下四种途径支持肝脏修复：
-
定向归巢与移植
MSCs 会响应炎症信号定向到肝损伤部位，并在少量情况下分化为类肝细胞，帮助恢复关键功能。 -
免疫调节
MSCs 分泌抗炎因子（如 IL‑10），可将免疫细胞引导至修复表型，减少破坏性炎症。 -
抗纤维化作用
通过调控 TGF‑β/Smad、STAT3、HGF 等信号通路，MSCs 抑制胶原蛋白产生细胞的激活，减缓或逆转瘢痕形成。 -
通过外泌体的旁分泌信号
MSCs 分泌的外泌体——纳米级囊泡——载有蛋白、脂质和 RNA，可重编程受损细胞并促进再生。
外泌体：无细胞修复模块
外泌体尺寸仅有 30–150 nm，但拥有强大疗效。与全细胞疗法相比，MSC 衍生外泌体具有：
-
无肿瘤风险：无法无限制增殖。
-
免疫原性低：表面抗原更少。
-
存储稳定：可长期保存且不失活性。
主要治疗特性包括：
-
抗铁死亡保护
外泌体稳定铁转运蛋白，防止急性损伤模型中的铁依赖性细胞死亡。 -
免疫调节
它们递送 microRNA 和抗炎蛋白，抑制关键炎性小体通路，减轻有害免疫风暴。 -
抗纤维化协同作用
外泌体载荷可增强胶原降解，并通过 Wnt/β‑catenin、PTEN/AKT 等通路抑制纤维化信号。 -
靶向递送
表面修饰（如加入特定配体）可提升受损肝细胞的摄取效率，强化治疗精准度。
疾病特异性应用
急性肝衰竭与缺血再灌注损伤
研究表明，外泌体可降低 IL‑6、IL‑1β 和 TNF‑α 水平，并减少中性粒细胞的募集——这些都是再灌注损伤的关键环节。无细胞策略能够提供快速、救命的干预。
慢性纤维化与肝硬化
来源于骨髓和脂肪组织的 MSC 外泌体可抑制胶原产生细胞，减少瘢痕组织。
负载抗纤维化 microRNA 的工程化外泌体更能有效恢复细胞外基质平衡。
这些发现提示外泌体疗法可能减缓甚至逆转纤维化进程，降低硬化并发症风险。
肝细胞癌
外泌体可向肿瘤细胞输送促凋亡和抗血管生成信号。
通过富集特定 microRNA，可增强癌细胞对化疗的敏感性，靶向抑制促生长通路。
这种无细胞方式有望成为 RNA 载体的精准递送工具，用于癌症治疗。
从实验室到临床：临床见解
-
早期试验：在急‑慢性肝衰竭患者中输注 MSCs 可改善肝功能评分，并提高六个月存活率；对失代偿性硬化患者的治疗安全可行，可提升患者生活质量。
-
下一步：仍需更大规模的Ⅲ期试验，以明确最佳剂量、给药途径及长期收益。
实践意义与未来方向
-
标准化：在良好生产规范（GMP）条件下的稳定生产，可确保批次间疗效一致。
-
机制阐明：明确哪些外泌体组分驱动特定修复通路，有助于优化疗法。
-
联合策略：将外泌体与小分子或预处理剂联合应用，或可实现协同增效。
-
安全监测：尽管外泌体无致瘤风险，但仍需密切监测离靶效应和免疫反应。
结论
MSCs 及其外泌体代表了肝病治疗的有希望前沿。通过定向归巢、免疫调节、抗纤维化信号传递和精准载荷递送，这些策略有望克服现有药物和移植的诸多局限。随着研究向标准化、大规模临床试验推进，MSC 衍生外泌体或将成为再生肝脏学的重要支柱。
Reference:
Shaolong Yang, Juanyu Liu, Jia Siang Khe, Alvin Jiunn Hieng Lu, Vuanghao Lim
Emerging insights into mesenchymal stem cells and exosome-based therapies for liver injury.
Biomol Biomed [Internet]. 2025 May 5 [cited 2025 Jul. 23];
Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12144
Additional information:
We invite submissions for our upcoming thematic issues, including:
- Immune Prediction and Prognostic Biomarkers in Immuno-Oncology
- Artificial Intelligence and Machine Learning in disease diagnosis and treatment target identification
More news: Blog
Editor: Merima Hadžić
Leave a Reply